Moderate persistent asthma with (acute) exacerbation
Methodology & AI Transparency ⓘ
Moderate persistent asthma with (acute) exacerbation Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Moderate persistent asthma with (acute) exacerbation—coded clinically as J45.41 across Lungs & Asthma guidelines—combines FeNO/eosinophil Type-2 inflammation in Moderate persistent asthma with (acute) exacerbation (J45.41: phenotyping) with structured follow-up of Spirometry FEV1 / in Moderate persistent asthma with (acute) exacerbation (J45.41: FVC Ratio) (>= 0.75 (FEV1 >= 80% predicted) (J45.41)).
- 2 Real-world patient consensus: Clinical coding for Moderate persistent asthma with (acute) exacerbation uses ICD-10 J45.41 across Lungs & Asthma specialty care.
- 3 Typical cash cost range: Primary evaluation for Moderate persistent asthma with (acute) exacerbation incorporates FeNO/eosinophil Type-2 inflammation in Moderate persistent asthma with (acute) exacerbation (J45.41: phenotyping) and symptom diary review.
- 4 Top reported side effects / signs: Longitudinal Moderate persistent asthma with (acute) exacerbation monitoring tracks Blood Eosinophil Count [Moderate persistent asthma with (acute) exacerbation J45.41] toward < 150 cells/uL (phenotyping marker) (J45.41).
Ask our AI Specialists anything about Moderate persistent asthma with (acute) exacerbation
What Is Moderate persistent asthma with (acute) exacerbation?
Moderate persistent asthma with (acute) exacerbation—coded clinically as J45.41 across Lungs & Asthma guidelines—combines FeNO/eosinophil Type-2 inflammation in Moderate persistent asthma with (acute) exacerbation (J45.41: phenotyping) with structured follow-up of Spirometry FEV1 / in Moderate persistent asthma with (acute) exacerbation (J45.41: FVC Ratio) (>= 0.75 (FEV1 >= 80% predicted) (J45.41)).
Pathophysiology, Underlying Causes & Clinical Presentation
Mechanistic hallmarks of Moderate persistent asthma with (acute) exacerbation (J45.41) center on dynamic expiratory airflow in Moderate persistent asthma with (acute) exacerbation (J45.41: limitation). targeted lungs & asthma interventions aim to normalize Blood Eosinophil Count [Moderate persistent asthma with (acute) exacerbation J45.41].
Common Symptoms & Clinical Signs
- • Presentation of Moderate persistent asthma with (acute) exacerbation (J45.41): declining stair-climbing stamina in Moderate persistent asthma with (acute) exacerbation (J45.41: or frequent rescue)
- • Secondary Moderate persistent asthma with (acute) exacerbation clinical sign: episodic wheezing, expiratory in Moderate persistent asthma with (acute) exacerbation (J45.41: chest tightness, or)
- • Symptom flares in Moderate persistent asthma with (acute) exacerbation correlating with Blood Eosinophil Count [Moderate persistent asthma with (acute) exacerbation J45.41] deviation outside < 150 cells/uL (phenotyping marker) (J45.41)
- • Functional lungs & asthma impact requiring FeNO/eosinophil Type-2 inflammation in Moderate persistent asthma with (acute) exacerbation (J45.41: phenotyping) evaluation (J45.41)
Moderate persistent asthma with (acute) exacerbation Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | J45.41 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Asthma, COPD & Respiratory Disease | NLM Clinical Tables |
| Diagnostic / Lab Marker: Blood Eosinophil Count [Moderate persistent asthma with (acute) exacerbation J45.41] | < 150 cells/uL (phenotyping marker) (J45.41) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Spirometry FEV1 / in Moderate persistent asthma with (acute) exacerbation (J45.41: FVC Ratio) | >= 0.75 (FEV1 >= 80% predicted) (J45.41) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fractional Exhaled Nitric in Moderate persistent asthma with (acute) exacerbation (J45.41: Oxide (FeNO)) | < 25 ppb (J45.41) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Moderate persistent asthma with (acute) exacerbation
Treatment selection for Moderate persistent asthma with (acute) exacerbation depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Moderate persistent asthma with (acute) exacerbation)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Skin-applied tazarotene in the treatment of mild to moderate: What a 468-Participant Study Found In general, 'using the cream formulation rather than the gel formulation optimized tolerability. Cutis • 2004-10-15 • Meta-Analysis | N = 468 | 97/100 | PMID 15543714 ↗ |
| New Insights on Safety of Fezolinetant for Treatment of Moderate to Severe Vasomotor Symptoms Due: What a 952-Participant Study Found Pooled data confirm the safety and tolerability of fezolinetant over 52 weeks. Advances in therapy • 2025-02-15 • Meta-Analysis | N = 952 | 97/100 | PMID 39739195 ↗ |
| New Insights on Telmisartan plus amlodipine in patients with moderate or severe high blood: What a 1,078-Participant Study Found Telmisartan plus amlodipine provides effective BP lowering at all clinically relevant doses (up to -26.5 mm Hg SBP), and almost 9 out of 10 patients may achieve DBP control. Postgraduate medicine • 2009-03-15 • Randomized Controlled Trial | N = 1,078 | 96/100 | PMID 19332958 ↗ |
| New Insights on Estradiol and progesterone bioavailability for moderate to severe vasomotor: What a 1,835-Participant Study Found P4 levels observed with TX-001HR were similar in the phase 1 and 3 studies, and were associated with no endometrial hyperplasia with either E2 daily dose over 1 year in the REPLENISH phase 3 study, which showed significant... Menopause (New York, N.Y.) • 2019-07-15 • Phase III Randomized Trial | N = 1,835 | 96/100 | PMID 30694918 ↗ |
| New Insights on Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin: What a 2,067-Participant Study Found Evolocumab reduced LDL-C levels by 66% (95% CI, 58% to 73%) to 75% (95% CI, 65% to 84%) (every 2 weeks) and by 63% (95% CI, 54% to 71%) to 75% (95% CI, 67% to 83%) (monthly) vs placebo at the mean of weeks 10 and 12 in the... JAMA • 2014-05-14 • Phase III Randomized Trial | N = 2,067 | 96/100 | PMID 24825642 ↗ |
Moderate persistent asthma with (acute) exacerbation Patient Community & “People Like Me” Threads
Filter Moderate persistent asthma with (acute) exacerbation community threads and patient logs by age, biological sex, dosage, and treatment duration.